MBMS, LLC’s Post

#biomedicalengineering #htm #patientsafety Here's a great resource link to the FDA's Center for Device & Radiological Health news and reports. Give them a visit on YouTube and remember it's your right to report medical device adverse reports to this proactive patient safety centric organization. MedWatch will always be there for the healthcare community.

"A Journey Through Tapering,” authored by Maritime SPOR SUPPORT Unit Patient/Public Partner Linda Wilhelm, reflects on her journey of tapering off prescription opioids. She covers several issues relevant to many patients, researchers, clinicians and most importantly policy-makers, shedding light on the importance of appropriate opioid prescriptions, the lack of support for opioid-dependent patients and the need for comprehensive healthcare solutions: https://lnkd.in/e4zQrH3W

New on-demand web-based activity: Optimizing Ready-to-Administer IV Push Products: A Multidisciplinary Approach to Safety, Cost-Effectiveness, and Patient Outcomes in Health System and Perioperative Settings This educational activity examines the landscape of considerations regarding ready-to-administer IV push products compared with traditional IV vial products, the holistic costs of waste, and new evidence regarding perioperative opioid use and associated adverse clinical outcomes. https://hubs.ly/Q02CVN0j0

Exciting developments in #RespiratoryCare and #ClinicalTrials! Strados Labs is at the forefront, innovating in ways that could significantly improve patient outcomes. Their technology captures real-time respiratory data, which is crucial for better diagnostics and treatments. As a professional passionate about healthcare innovation, I find their approach to respiratory health especially promising. Leveraging technology in clinical settings can lead to breakthroughs that were previously out of reach. What are your thoughts on the integration of such technologies in clinical practices? Could this be the future of personalized healthcare? #RespiratoryHealth #HealthTech #Innovation

#DYK The Food and Drug Omnibus Reform Act (FDORA) now requires certain clinical studies to submit Diversity Action Plans that ensure demographic factors in patient population? Enhancing diversity within clinical studies ensures greater representation in trials and facilitates broader applicability of results across a broad spectrum of patient populations. Talk to one of our experts today to understand how AliveCor’s patient-friendly technology solution for cardiac safety meets new diversity standards and your trial requirements. Schedule a demo: https://lnkd.in/gVzNTtxm #ClinicalTrials #ClinicalResearch #ECG #CardiacMonitoring #AliveCor

Pharmacy burnout and institutional fatigue is at a critical level. #Pharmacist Dr. Angela German discussed often-overlooked contributing factors in a recent Scottsdale Institute webinar. Read our Expert Insight to learn more and access the replay. https://ow.ly/vKUB50QziNL #RetailPharmacy #PharmacistBurnout #FutureReadyPharmacy

🎉 Check out our latest paper A Retrospective Analysis of the Clinical Effectiveness of Tigecycline in the Treatment of Clostridioides difficile-Associated Diarrhea https://lnkd.in/gMkshdU3 #antimicrobialstewardship #Clostridioidesdifficile #Tigecycline

❗️ ‘Drugs don’t work in patients who don’t take them’. (C. Everett Koop) 💊This obvious truth, expressed by Dr C. Everett Koop, a former American surgeon, is often cited in publications devoted to medication adherence, highlighting the fact that there is an urgent need to put treatment adherence high enough in therapeutic interest of a medicine. ➡️Aging of people, among all, urges us to take the problem seriously. ➡️We should look for innovative medicine tailored for adherence enhancement and encourage technical innovations in this area. 🔥Lauriad® is conceived to optimize medication compliance by a targeted action at the site of infection, releasing an early, effective and prolonged concentration of an active substance, thus enabling a limitation of drug taking.  👉To know more about the technology: https://lnkd.in/d3MVBp77  👉To know more about medication compliance: “From non-adherence to adherence: Can innovative solutions resolve a longstanding problem?” (2024) https://lnkd.in/gZsnsQtg #Innovation #Compliance #Lauriad

André Sattler, Business Development Manager, and Daniela Fonseca Chagas, Multicare Consultant, attended an event called "Neonatal Screening & Rare Diseases" at Casa Hunter - Associação Brasileira de Doenças Raras today. The event aimed to discuss the new legislation on Neonatal Screening, Nº 14.154, which has expanded the testing scope from 6 to 54 diseases. This new law represents a significant step forward in healthcare, as it has the potential to save lives and positively impact society. Renowned specialists in the field were invited to speak on essential topics, including the importance of early diagnosis of rare diseases, which is critical to ensure appropriate treatment and improve the quality of life for patients. The speakers also discussed the challenges and opportunities presented by the new law, including how to ensure effective implementation and universal access to the expanded test. Additionally, the role of technology and innovation in neonatal screening was discussed, including solutions that can optimize the process and increase the accuracy of results. Lastly, congratulations to Casa Hunter for hosting such an informative event. Together, we can work towards building a better future. #NeonatalScreening #RareDiseases #PublicHealth #CasaHunter #Consulting #Innovation

New on-demand web-based activity: "Optimizing Ready-to-Administer IV Push Products: A Multidisciplinary Approach to Safety, Cost-Effectiveness, and Patient Outcomes in Health System and Perioperative Settings" This educational activity examines the landscape of considerations regarding ready-to-administer IV push products compared with traditional IV vial products, the holistic costs of waste, and new evidence regarding perioperative opioid use and associated adverse clinical outcomes. Learn more: https://hubs.ly/Q02lmv9L0